In this study, AMY significantly altered the expressions of SREBP1 and PPAR-α, and inhibited the lipogenic factors CD36, FAS, and ACC in hepatic tissues, indicating that AMY ameliorated NAFLD through the suppression of lipogenesis and the promotion of fatty acid oxidation. Here, FAS is linked to metabolic dysfunction-associated steatotic liver disease.